Rola rekombinowanych erytropoetyn w leczeniu niedokrwistości w przebiegu choroby nowotworowej Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2017
Słowa kluczowe:
erytropoetyna, niedokrwistość, nowotwór, chemioterapia
##plugins.themes.bootstrap3.article.main##
Abstrakt
Niedokrwistość jest jednym z najczęstszych efektów zaburzenia funkcji układu hematopoetycznego u chorych na nowotwory. W chwili rozpoznania choroby nowotworowej diagnozuje się ją u 30% nieleczonych i 60–70% otrzymujących chemioterapię lub radioterapię. Metoda leczenia niedokrwistości zależy od: nasilenia zaburzenia, stosowanej terapii i objawów klinicznych; może ona polegać na przyjęciu postawy wyczekującej, wdrożeniu rekombinowanych erytropoetyn lub przetoczeniu koncentratu krwinek czerwonych zgodnych grupowo. Erytropoetyna to hormon glikoproteinowy syntetyzowany w warunkach fizjologicznych głównie przez komórki śródmiąższowe nerki (ok. 90%). Obecnie rutynowo stosowane są 3 ludzkie rekombinowane erytropoetyny mające zbliżone mechanizmy działania. To epoetyna α, epoetyna β, oraz darbepoetyna α. Podawanie rekombinowanych erytropoetyn ludzkich może się wiązać także z wymierną korzyścią terapeutyczną przejawiającą się zwiększoną odpowiedzią komórek nowotworowych na cytostatyki. Stosowanie erytropoetyn wiąże się jednak z wysokim ryzykiem powikłań, w tym zakrzepowo-zatorowych. Wynika ono z samej choroby nowotworowej i towarzyszącej jej niejednokrotnie nadpłytkowości, a potęguje je dodatkowo występowanie w wywiadzie: zabiegów chirurgicznych, długotrwałego unieruchomienia, stosowania preparatów hormonalnych, nadciśnienia tętniczego i powikłań zakrzepowo-zatorowych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Kubiatowski , T., & Jankowski, T. (2017). Rola rekombinowanych erytropoetyn w leczeniu niedokrwistości w przebiegu choroby nowotworowej . Medycyna Faktów , 10(1(34), 14-21. Pobrano z https://www.journalsmededu.pl/index.php/jebm/article/view/2163
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Czyż A.: Powikłania hematologiczne. W: Krzakowski M., Potemski P., Warzocha K., Wysocki P. (red.): Onkologia Kliniczna. Via Medica, Gdańsk 2014.
2. Ludwig H., Van Belle S., Barrett-Lee P. et al.: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer 2004; 40(15): 2293-2306.
3. Wilson J., Yao G.L., Raftery J. et al.: A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol. Assess. 2007; 11(13): 1-202.
4. Radziwon P.: Dlaczego warto rozważyć stosowanie leków stymulujących erytropoezę w niedokrwistości u chorych na nowotwory. Medycyna Faktów 2016; 4(33): 357-364.
5. Prada-Turska J., Paluszkiewicz P.: Leki wpływające na czynność krwiotwórczą szpiku. W: Rajtar-Cynke G. (red.): Farmakologia. Wydawnictwo Lekarskie PZWL, Warszawa 2015.
6. Littlewood T.J., Bajetta E., Nortier J.W. et al.; Epoetin Alfa Study Group: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 2001; 19(11): 2865-2874.
7. Tonia T., Mettler A., Robert N. et al.: Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst. Rev. 2012; 12: CD003407.
8. Foubert J.: New EORTC guidelines for the treatment of anaemia in patients with cancer: Implications for nursing practice. Eur. J. Oncol. Nurs. 2006; 10: 177-186.
9. Schrijvers D., De Samblanx H., Roila F.; on behalf of the ESMO Guidelines Working Group: Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann. Oncol. 2010; 21(supl. 5): v244-v247.
10. Rizzo D.J., Brouwers M., Hurley P. et al.: American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer. J. Clin. Oncol. 2010; 28(33): 4996-5010.
11. Cancer and chemotherapy-induced anemia [online: www.nccn.org].
12. Bennett C.L., Silver S.M., Djulbegovic B. et al.: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299(8): 914-924.
13. Bennett S.L., Henke M., Lai S.Y.: Erythropoiesis-stimulating agents in the treatment of cancer-related anemia-reply. JAMA 2008; 300: 2855-2857.
14. Bohlius J., Schmidlin K., Brillant C. et al.: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta- analysis of randomised trials. Lancet 2009; 373(9674): 1532-1542.
15. Tonelli M., Hemmelgarn B., Reiman T. et al.: Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009; 180(11): E62-71.
16. Engert A., Josting A., Haverkamp H. et al.: Epoetin alfa in patients with advanced-stage Hodgkin’s lymphoma: results of the randomized placebo- controlled GHSG HD15EPO trial. J. Clin. Oncol. 2010; 28(13): 2239-2245.
17. Glaspy J., Crawford J., Vansteenkiste J. et al.: Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br. J. Cancer 2010; 102(2): 301-315.
18. Ludwig H., Crawford J., Osterborg A. et al.: Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J. Clin. Oncol. 2009; 27(17): 2838-2847.
19. Moebus V., Jackisch C., Lueck H.J. et al.: Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J. Clin. Oncol. 2010; 28(17): 2874-2880.
20. Untch M., Fasching P.A., Konecny G.E. et al.; Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators: PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer – results at the time of surgery. Ann. Oncol. 2011; 22(9): 1988-1998.
21. Untch M., von Minckwitz G., Konecny G.E. et al.: PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin – cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer – outcome on prognosis. Ann. Oncol. 2011; 22(9): 1999-2006.
22. Grote T., Yeilding A.L., Castillo R. et al.: Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double- blind, placebo-controlled trial. J. Clin. Oncol. 2005; 23(36): 9377-9386.
23. Pirker R., Ramlau R.A., Schuette W. et al.: Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J. Clin. Oncol. 2008; 26(14): 2342-2349.
24. Heit J.A., Silverstein M.D., Mohr D.N. et al.: Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch. Intern. Med. 2000; 160(6): 809-815.
25. Khorana A.A., Francis C.W., Culakova E. et al.: Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J. Thromb. Haemost. 2007; 5(3): 632-634.
26. Levine M.N., Gent M., Hirsh J. et al.: The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N. Engl. J. Med. 1988; 318(7): 404-407.
27. Lyman G.H., Khorana A.A., Falanga A. et al.; American Society of Clinical Oncology: American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J. Clin. Oncol. 2007; 25(34): 5490-5505.
28. Saphner T., Tormey D.C., Gray R.: Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J. Clin. Oncol. 1991; 9(2): 286-294.
29. Glaspy J., Crawford J., Vansteenkiste J. et al.: Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br. J. Cancer 2010; 102: 301-315.
30. Besarab A., Bolton W.K., Browne J.K. et al.: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 1998; 339(9): 584-590.
31. Besarab A., Goodkin D.A., Nissenson A.R.; Normal Hematocrit Cardiac Trial Authors: The normal hematocrit study – follow-up. N. Engl. J. Med. 2008; 358(4): 433-434.
32. Imai E., Yamamoto R., Suzuki H., Watanabe T.: Incidence of symptomatic stroke and cancer in chronic kidney disease patients treated with epoetins. Clin. Exp. Nephrol. 2010; 14(5): 445-452.
33. Pfeffer M.A., Burdmann E.A., Chen C.Y. et al.; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 2009; 361(21): 2019-2032.
34. Seliger S.L., Zhang A.D., Weir M.R. et al.: Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int. 2011; 80(3): 288-294.
35. Singh A.K., Szczech L., Tang K.L. et al.; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 2006; 355(20): 2085-2098.
36. Debeljak N., Solár P., Sytkowski A.J.: Erythropoietin and cancer: the unintended consequences of anemia correction. Front. Immunol. 2014; 5: 563.
37. Sytkowski A.J.: Erythropoietin: Blood, Brain and Beyond. Wiley-VCH, Weinheim 2004.
38. Barquilla A., Pasquale E.B.: Eph receptors and ephrins: therapeutic opportunities. Annu. Rev. Pharmacol. Toxicol. 2015; 55: 465-487.
39. Gokmen-Polar Y., Toroni R.A., Hocevar B.A. et al.: Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. Breast Cancer Res. Treat. 2011; 127: 375-384.
40. Lu M., Miller K.D., Gokmen-Polar Y. et al.: EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res. 2003; 63: 3425-3429.
41. Zhuang G., Brantley-Sieders D.M., Vaught D. et al.: Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res. 2010; 70: 299-308.
42. Li J.L., Sainson R.C., Oon C.E. et al.: DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 2011; 71: 6073-6083.
43. Stahl S., Kaminskyy V.O., Efazat G. et al.: Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412. Cell Death Dis. 2013; 4: e454.
2. Ludwig H., Van Belle S., Barrett-Lee P. et al.: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer 2004; 40(15): 2293-2306.
3. Wilson J., Yao G.L., Raftery J. et al.: A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol. Assess. 2007; 11(13): 1-202.
4. Radziwon P.: Dlaczego warto rozważyć stosowanie leków stymulujących erytropoezę w niedokrwistości u chorych na nowotwory. Medycyna Faktów 2016; 4(33): 357-364.
5. Prada-Turska J., Paluszkiewicz P.: Leki wpływające na czynność krwiotwórczą szpiku. W: Rajtar-Cynke G. (red.): Farmakologia. Wydawnictwo Lekarskie PZWL, Warszawa 2015.
6. Littlewood T.J., Bajetta E., Nortier J.W. et al.; Epoetin Alfa Study Group: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 2001; 19(11): 2865-2874.
7. Tonia T., Mettler A., Robert N. et al.: Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst. Rev. 2012; 12: CD003407.
8. Foubert J.: New EORTC guidelines for the treatment of anaemia in patients with cancer: Implications for nursing practice. Eur. J. Oncol. Nurs. 2006; 10: 177-186.
9. Schrijvers D., De Samblanx H., Roila F.; on behalf of the ESMO Guidelines Working Group: Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann. Oncol. 2010; 21(supl. 5): v244-v247.
10. Rizzo D.J., Brouwers M., Hurley P. et al.: American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer. J. Clin. Oncol. 2010; 28(33): 4996-5010.
11. Cancer and chemotherapy-induced anemia [online: www.nccn.org].
12. Bennett C.L., Silver S.M., Djulbegovic B. et al.: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299(8): 914-924.
13. Bennett S.L., Henke M., Lai S.Y.: Erythropoiesis-stimulating agents in the treatment of cancer-related anemia-reply. JAMA 2008; 300: 2855-2857.
14. Bohlius J., Schmidlin K., Brillant C. et al.: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta- analysis of randomised trials. Lancet 2009; 373(9674): 1532-1542.
15. Tonelli M., Hemmelgarn B., Reiman T. et al.: Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009; 180(11): E62-71.
16. Engert A., Josting A., Haverkamp H. et al.: Epoetin alfa in patients with advanced-stage Hodgkin’s lymphoma: results of the randomized placebo- controlled GHSG HD15EPO trial. J. Clin. Oncol. 2010; 28(13): 2239-2245.
17. Glaspy J., Crawford J., Vansteenkiste J. et al.: Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br. J. Cancer 2010; 102(2): 301-315.
18. Ludwig H., Crawford J., Osterborg A. et al.: Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J. Clin. Oncol. 2009; 27(17): 2838-2847.
19. Moebus V., Jackisch C., Lueck H.J. et al.: Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J. Clin. Oncol. 2010; 28(17): 2874-2880.
20. Untch M., Fasching P.A., Konecny G.E. et al.; Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators: PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer – results at the time of surgery. Ann. Oncol. 2011; 22(9): 1988-1998.
21. Untch M., von Minckwitz G., Konecny G.E. et al.: PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin – cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer – outcome on prognosis. Ann. Oncol. 2011; 22(9): 1999-2006.
22. Grote T., Yeilding A.L., Castillo R. et al.: Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double- blind, placebo-controlled trial. J. Clin. Oncol. 2005; 23(36): 9377-9386.
23. Pirker R., Ramlau R.A., Schuette W. et al.: Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J. Clin. Oncol. 2008; 26(14): 2342-2349.
24. Heit J.A., Silverstein M.D., Mohr D.N. et al.: Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch. Intern. Med. 2000; 160(6): 809-815.
25. Khorana A.A., Francis C.W., Culakova E. et al.: Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J. Thromb. Haemost. 2007; 5(3): 632-634.
26. Levine M.N., Gent M., Hirsh J. et al.: The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N. Engl. J. Med. 1988; 318(7): 404-407.
27. Lyman G.H., Khorana A.A., Falanga A. et al.; American Society of Clinical Oncology: American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J. Clin. Oncol. 2007; 25(34): 5490-5505.
28. Saphner T., Tormey D.C., Gray R.: Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J. Clin. Oncol. 1991; 9(2): 286-294.
29. Glaspy J., Crawford J., Vansteenkiste J. et al.: Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br. J. Cancer 2010; 102: 301-315.
30. Besarab A., Bolton W.K., Browne J.K. et al.: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 1998; 339(9): 584-590.
31. Besarab A., Goodkin D.A., Nissenson A.R.; Normal Hematocrit Cardiac Trial Authors: The normal hematocrit study – follow-up. N. Engl. J. Med. 2008; 358(4): 433-434.
32. Imai E., Yamamoto R., Suzuki H., Watanabe T.: Incidence of symptomatic stroke and cancer in chronic kidney disease patients treated with epoetins. Clin. Exp. Nephrol. 2010; 14(5): 445-452.
33. Pfeffer M.A., Burdmann E.A., Chen C.Y. et al.; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 2009; 361(21): 2019-2032.
34. Seliger S.L., Zhang A.D., Weir M.R. et al.: Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int. 2011; 80(3): 288-294.
35. Singh A.K., Szczech L., Tang K.L. et al.; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 2006; 355(20): 2085-2098.
36. Debeljak N., Solár P., Sytkowski A.J.: Erythropoietin and cancer: the unintended consequences of anemia correction. Front. Immunol. 2014; 5: 563.
37. Sytkowski A.J.: Erythropoietin: Blood, Brain and Beyond. Wiley-VCH, Weinheim 2004.
38. Barquilla A., Pasquale E.B.: Eph receptors and ephrins: therapeutic opportunities. Annu. Rev. Pharmacol. Toxicol. 2015; 55: 465-487.
39. Gokmen-Polar Y., Toroni R.A., Hocevar B.A. et al.: Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. Breast Cancer Res. Treat. 2011; 127: 375-384.
40. Lu M., Miller K.D., Gokmen-Polar Y. et al.: EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res. 2003; 63: 3425-3429.
41. Zhuang G., Brantley-Sieders D.M., Vaught D. et al.: Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res. 2010; 70: 299-308.
42. Li J.L., Sainson R.C., Oon C.E. et al.: DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res. 2011; 71: 6073-6083.
43. Stahl S., Kaminskyy V.O., Efazat G. et al.: Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412. Cell Death Dis. 2013; 4: e454.